GSK receives expanded approval for Shingrix in China for adults at risk
PositiveFinancial Markets

GSK has received expanded approval for its shingles vaccine, Shingrix, in China, specifically targeting adults at risk. This is a significant development as it enhances access to an effective preventive measure against shingles, a painful condition that can lead to serious complications. The approval not only reflects GSK's commitment to public health but also addresses a critical need in the aging population of China, where the incidence of shingles is rising.
— Curated by the World Pulse Now AI Editorial System